G1 Therapeutics Reaffirms 2024 Net COSELA Revenue Guidance Of $60M-$70M, Expects Cash Runway To Extend Into Q3 Of 2025
Portfolio Pulse from Benzinga Newsdesk
G1 Therapeutics reaffirmed its 2024 net COSELA revenue guidance of $60M-$70M, expecting its cash runway to extend into Q3 of 2025. This outlook is based on anticipated acceleration of COSELA sales in the U.S.
May 01, 2024 | 10:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
G1 Therapeutics expects to maintain strong sales growth for COSELA, projecting 2024 revenues of $60M-$70M and extending its cash runway into Q3 2025.
The reaffirmation of revenue guidance and the extension of the cash runway signal confidence in COSELA's market performance and G1 Therapeutics' financial planning. This positive outlook is likely to reassure investors about the company's growth trajectory and financial stability, potentially leading to a positive short-term impact on GTHX's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100